Ligand Pharmaceuticals LGND Preferred Stock, Par or Stated Value Per Share
Preferred Stock, Par or Stated Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's preferred stock, par or stated value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's preferred stock, par or stated value per share?
- Ligand Pharmaceuticals (LGND) reported preferred stock, par or stated value per share of $0 in Q1 2026.
- How has Ligand Pharmaceuticals's preferred stock, par or stated value per share changed year-over-year?
- Ligand Pharmaceuticals's preferred stock, par or stated value per share decreased by 0.0% year-over-year, from $0 to $0.
- What is the long-term trend for Ligand Pharmaceuticals's preferred stock, par or stated value per share?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's preferred stock, par or stated value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.